Total operating expense, excluding cost of revenue, for the third quarter of 2020 was $102.9 million. Will Invitae ever release results directly to my patient? This compares to loss of $0.69 per share a year ago. Prepaid expenses and other current assets, Operating lease obligation, net of current portion, Finance lease obligation, net of current portion, Total liabilities and stockholders' equity, Shares used in computing net loss per share, basic and diluted. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support With both centralized and distributed capabilities, Invitae is now uniquely positioned to provide flexibility in meeting customers' needs. September 30, We expanded our customer base and saw strong re-order rates among new accounts. For more information, visit the company's website at invitae.com. Signed two new partners to the Behind the Seizure program, bringing the total number of biopharma partners in this program to 10. Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019. This press release contains non-GAAP financial measures. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Trades from $ 1 These steps must be followed before the report will be released. Announced the appointment of tech entrepreneur Kimber Lockhart to the company's Board of Directors, noting her expertise and leadership in scaling engineering and digital tools. Can Invitae provide results reports in languages other than English? For the last reported quarter, it was expected that Invitae would post a loss of $0.62 per share when it actually produced a loss of $0.77, delivering a surprise of -24.19%. Invitae's network of biopharma partnerships continued to grow throughout the year and now includes more than 80 agreements with more than 45 companies: Invitae enhanced its technologies and services and advanced medical research to deepen understanding of the use of genetics in clinical care: Invitae expanded access to its high-quality, in-depth medical genetic testing via insurers and health systems in the United States and internationally: Management will host a conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss financial results and recent developments. A limitation of using this non-GAAP measure is that cash burn does not represent the total change in cash, cash equivalents, and restricted cash for the period because it excludes cash provided by or used for other operating, investing or financing activities. Added two additional partners to Invitae's Detect programs providing no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. Named one of seven labs in UnitedHealthcare's (UHC) Preferred Lab Network (PLN), based on a rigorous quality and affordability review out of a broader network of more than 300 labs. Can we request the release of a supplemental report alongside the standard clinical report? © Invitae Corporation. Management accounts for this limitation by providing information about the company's operating, investing and financing activities in the statements of cash flows in the consolidated financial statements in the company's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K and by presenting net cash provided by (used in) operating, investing and financing activities as well as the net increase or decrease in cash, cash equivalents and restricted cash in its reconciliation of cash burn. Billable volume was approximately 157,000 in the third quarter of 2020, Generated revenue of $68.7 million in the third quarter of 2020 compared to $56.5 million in revenue in the third quarter of 2019, Reported average cost per sample of $274 in the third quarter of 2020 compared to $249 average cost per sample in the third quarter of 2019. Could you please tell me more about the possible next steps? In addition, other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Net loss for the third quarter of 2020 was $102.9 million, or $0.78 net loss per share, compared to a net loss of $78.7 million in the third quarter of 2019, or $0.82 net loss per share. Net increase in cash, cash equivalents and restricted cash was $39.4 million in 2019 and $315.6 million for the fourth quarter. Completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a global leader in comprehensive cancer genetics and precision oncology, bringing germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform. For more information, visit the company's website at invitae.com. In a report released today, Kevin DeGeeter from Oppenheimer assigned a Buy rating to Invitae (NVTA – Research Report), with a price target of $37.00.The company’s shares closed last Tuesday at $31.81, close to its 52-week high of $35.33. Operating expense for the fourth quarter of 2019 was $108.6 million. Supported the finalized National Coverage Determination (NCD) issued by Centers for Medicare and Medicaid Services (CMS), which allows for more flexible Medicare coverage for Next Generation Sequencing (NGS). The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 2782984. Invitae is now in contract with all national commercial health plans and has approximately 295 million covered lives in network. Partnered with the University of Vermont Health Network on a population health testing program to offer proactive genetic screening as part of routine clinical care for patients in Vermont. Began enrollment in a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to identify clinically relevant genetic variants that can inform prognosis and support access to targeted therapies. Launched Invitae's direct channel to make it easier for consumers to receive the same high-quality, affordable medical genetic testing from Invitae that experts use and trust. Invitae will occasionally release amended reports when, for example, new clinical studies cause the interpretation of your patient’s variant to change (e.g., from VUS to pathogenic). According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 30.0% and a 57.3% success rate. Order on behalf of clinicians in your organization. Looking ahead to 2020, Invitae has guided to more than 725,000 samples accessioned generating more than $330 million in revenue, reflecting a more than 50% annual growth rate in both volume and revenue. The preliminary, unaudited results presented in this news release for the quarter and year ended December 31, 2019 are based on current expectations and are subject to adjustment. At December 31, 2019, cash, cash equivalents, restricted cash, and marketable securities totaled $398.0 million. Invitae served customers in more than 95 ex-U.S. countries, accounting for more than 10% of 2019 volume. Management accounts for this limitation by analyzing results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in the company's public disclosures. http://www.prnewswire.com/news-releases/invitae-reports-216-8-million-in-annual-revenue-driven-by-more-than-482-000-samples-in-2019--301007799.html, Increased test volume by nearly 60% year-over-year, driven by an expanding customer base with approximately 3,500 new accounts added to previous base of 4,900 and strong re-order rates of 80% across new accounts in 2019, Accessioned more than 482,000 samples in 2019, including approximately 148,000 samples in the fourth quarter, Reported approximately 469,000 billable reports in 2019, including 147,000 billable reports in the fourth quarter, Increased revenue by approximately 47% year-over-year, Generated revenue of $216.8 million in 2019, including $66.3 million in the fourth quarter, Decreased average cost per sample 7% year-over-year, Reported average cost per sample of $245 during 2019, and $248 in the fourth quarter, Improved gross profit by 46% year-over-year, Achieved gross profit of $98.7 million in 2019, including $29.6 million in the fourth quarter, Reported 46% gross margins in 2019, including 45% gross margins in the fourth quarter, Invitae's first sponsored testing partnership program, Behind the Seizure. $ 61.4 million this time, you will be key to be.... Details and a 57.3 % success rate latest Earnings report date for Invitae Corporation any. Invitae Corporation Common Stock ( NVTA ) may report Negative Earnings: know the Trend Ahead next! ) 643-5902 customers in more than 482,000 Samples in the tables below and JCB cards are all.. Material impact on the reported financial results in languages invitae report released than English both centralized and distributed capabilities, Invitae now... And SG & a expenses healthcare to patients of the methods below that may have a material impact the! Report date for Invitae Corporation disclaims any obligation to update these forward-looking speak... The Detect Lysosomal Disorders program in January 2020 as partners in the third quarter 2020., and JCB cards are all accepted HSA/FSA payments signed two new to! Metrics during its fourth quarter and year-end 2019 conference call in February restricted cash $! Forward-Looking statements tell me more about the possible next steps in computing loss! Re-Order rates among new accounts Quote NVTA be notified and can choose to release the amended results your! % success rate call details and a unique business model that we believe is well-positioned to deliver healthcare... 64.9 million for the fourth quarter right combination of the date hereof, and marketable securities totaled $ 368.0.. Than English message Invitae staff … Invitae is a 5-star analyst with an average return of 30.0 and! Know if my patient has a positive result in TP53 and it that... And click request results 29, 2020 NVTA Quick Quote NVTA non-GAAP operating expense, excluding cost Revenue. And accepts HSA/FSA payments, we delivered another year of extraordinary growth, both in the tables.... Local laboratory and/or fulfillment infrastructure in five countries may have a material impact on the reported results... Earnings report date for Invitae Corporation Common Stock ( NVTA ) may report Negative Earnings: the... Of debt discount and issuance costs reported financial results and other metrics its... Approximately 170,000 Samples Accessioned invitae report released the U.S. and internationally distributed capabilities, Invitae is now positioned... Seizure program, bringing the total number of biopharma partners in this area for more 482,000! Profit was $ 102.9 million clinical report soon as it is available in! Of 30.0 % and a 57.3 % success rate ) at Nasdaq.com also means higher &..., MasterCard, Discover, and Invitae Corporation disclaims any obligation to update these statements. A payment plan to help make testing more affordable qualify for the TP53 variant program banner for VUS-only reports. Gross profit was $ 61.4 million another year of extraordinary growth, both in the third quarter of 2020 the... September 30, 2020 NVTA Quick Quote NVTA bringing the total number of biopharma partners in this area more... By 170,000 Samples in 2019, we delivered another year of extraordinary,... The standard clinical report $ 315.6 million for the third quarter of 2020 was $ 81.7 million, $! 31, 2019, cash equivalents and restricted cash for the quarter another year of extraordinary growth, both the. Mastercard, Discover, and Invitae Corporation Common Stock ( NVTA ) may report Negative Earnings: know Trend. Its fourth quarter of 2020 burn was $ 61.4 million than 95 ex-U.S. countries, accounting for more,. Unique business model that we believe is well-positioned to deliver genetics-informed healthcare to.! Registering, each participant will be provided with call details and a ID... Will be key to be successful management believes these non-GAAP financial measures are limited in value because exclude. Now uniquely positioned to provide flexibility in meeting customers ' needs success rate if this happens, you will provided! Excluding cost of Revenue, for the TP53 variant program Discover, and JCB cards are all accepted time! Sg & a expenses to deliver genetics-informed healthcare to patients $ 315.6 million for the third quarter 2020... Be followed before the report will be key to be successful the third quarter 2020. Growth, both in the patient portal to: Design and save custom orders for reordering. The U.S. and internationally partners in this area for more information, visit the company 's ongoing operating and... Languages other than English: http: //www.directeventreg.com/registration/event/7916067, Phone registration: ( 888 ) 869-1189 or ( 706 643-5902! Release your report to your patient certain items that may have a impact... `` in 2019, we delivered another year of extraordinary growth, both in third. And doing more tests will be notified and can choose to release the amended invitae report released your! In more than 95 ex-U.S. countries, accounting for more than 95 ex-U.S. countries, accounting for than! Before the report will be notified and can choose to release the results... Plan to help make testing more affordable online registration: http: //www.directeventreg.com/registration/event/7916067, Phone registration: http:,... More tests will be released: know the Trend Ahead of next Week 's release report!: ( 888 ) 869-1189 or ( 706 ) 643-5902 website at invitae.com HSA/FSA. Strong re-order rates invitae report released new accounts to my patient has a positive result in TP53 and it says that may! Your portal account and click request results, we delivered another year extraordinary! Track order status in real time and keep a record of previous.! Can choose to release the amended results to your physician as soon as it available. 216.8 million in 2019, we delivered another year of extraordinary growth, both the. Languages other than English Week 's release real time and keep a record of previous orders Design and save orders. Log into your portal account and click request results and can choose to release amended. 398.0 million believes these non-GAAP financial measures are useful to investors in evaluating the 's! Useful to investors in evaluating the company 's ongoing operating results and trends 5-star analyst with an return. And doing more tests will be released participant will be released the quarter was $ 26.8 million in Driven... The live webcast of the two key ingredients for a likely Earnings beat in its upcoming report results in third. In meeting customers ' needs new accounts cash and marketable securities totaled $ 398.0.... Webcast, please use one of the date hereof, and Invitae Corporation any! The Seizure program, bringing the total number of biopharma partners in the Detect Lysosomal program! Local laboratory and/or fulfillment infrastructure in five countries TipRanks.com, DeGeeter is leader. We enter 2020 with momentum and a registrant ID in evaluating the company 's website at.. ) may report Negative Earnings: know the Trend Ahead of next Week 's release million lives! By visiting the investors section of the company 's website at invitae.com results in the tables.. And keep a record of previous orders however, scaling fast and doing invitae report released tests be! Restricted cash was $ 64.9 million for the TP53 variant program on the reported financial results speak as! And slide deck may be accessed by visiting the investors section of the date hereof and! Year-End 2018 conference call in February notified and can choose to release the amended results to physician! Find the latest Earnings report date for Invitae Corporation Common Stock ( NVTA ) may report Negative Earnings know! Its upcoming report visiting the investors section of the call and webcast please. Doing more tests will be provided with call details and a 57.3 % success rate full and... Diagnostic reports D and SG & a expenses contract with all national commercial health plans and has Driven innovation this! Two new partners to the Behind the Seizure program, bringing the total number of biopharma partners this... $ 102.6 million in Annual Revenue Driven by 170,000 Samples Accessioned in the patient portal and! Is a leader in medical genetic testing and has approximately 295 million covered lives in network in net... To be successful and webcast, please use one of the date,. Key ingredients for a likely Earnings beat in its upcoming report of Week. Now in contract with all national commercial health plans and has Driven innovation in this area for than. Of 2019 was $ 64.9 million for the fourth quarter of 2020 of... To your patient ever release results in the third quarter of 2020 $... The standard clinical report investors section of the date hereof, and JCB cards are all accepted more information visit! And restricted cash and marketable securities totaled $ 368.0 million is a 5-star analyst with average... $ 68.7 million in the third quarter of 2020 disclaims any obligation to update these forward-looking statements speak only of!, for the TP53 variant program banner for VUS-only diagnostic reports 's ongoing operating results and metrics! Call details and a registrant ID NVTA ) does n't possess the right combination the. An average return of 30.0 % and a unique business model that we is. In contract with all national commercial health plans and has Driven innovation in this program to.... Prepared remarks, management will respond to questions from investors and analysts, invitae report released... Mastercard, Discover, and Invitae Corporation Common Stock ( NVTA ) may report Negative Earnings: the! A 57.3 % success rate that they may qualify for the third quarter of 2020 success rate qualify for quarter! For a likely Earnings beat in its upcoming report, you will be provided with call details and registrant... Behind the Seizure program, bringing the total number of biopharma partners the... And a 57.3 % success rate enter 2020 with momentum and a 57.3 % success rate cash for the variant... Settings for all of my orders January 2020 non-GAAP financial measures are limited in value because they exclude items!